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Oxidative stress is one of the major pathological features of Alzheimer’s disease (AD). Here, we investigated whether dietary vitamin E
(VE) depletion may induce adverse effects and supplementation with a-tocopherol (aT) may result in beneficial effects on redox status and
the regulation of genes relevant in the pathogenesis of AD in healthy rats. Three groups of eight male rats each were fed diets with deficient
(,1mgaT equivalents/kg diet), marginal (9mgaT equivalents/kg diet) or sufficient (18mg aT equivalents/kg diet) concentrations of
natural-source VE for 6 months; a fourth group was fed the VE-sufficient diet fortified with aT (total VE, 146mgaT equivalents/kg diet). Feeding
of the experimental diets dose dependently altered aT concentrations in the cortex and plasma. No significant changes in F2-isoprostane concen-
trations, activities of antioxidative enzymes (total superoxide dismutase, Se-dependent glutathione peroxidase) and concentrations of glutathione or
the expression of AD-relevant genes were observed. In this non-AD model, depletion of VE did not induce adverse effects and supplementation of
aT did not induce positive effects on the parameters related to the progression of AD.
Vitamin E: Brain: Rat: Gene expression: Redox status: Alzheimer’s disease
Oxidative stress appears to be centrally involved in the
pathogenesis of Alzheimer’s disease (AD) and many of the
pathological processes involved in its development and pro-
gression are either caused by or lead to an augmented gener-
ation of reactive oxygen and nitrogen species(1). Therefore, the
importance of vitamin E (VE) for the maintenance of neuronal
integrity and brain function is becoming increasingly
recognised.
Epidemiological studies indicate that a high intake of VE
from food sources, but not from dietary supplements, may con-
tribute to the prevention of age-related neurodegenerative dis-
orders such as AD(2–4). Morris et al. evaluated the
contribution of the different VE congeners towards the preven-
tion of AD. While a higher dietary intake of both a-tocopherol
(aT) and g-tocopherol (gT) was associated with a decreased
risk of developingAD, their data suggested that the combination
of the differentVE isoformsmay bemore effective in preventing
AD than the intake of aT alone(4). In line with this, in some
intervention studies, supplementation of high doses of aT, the
major lipid-soluble antioxidant in human plasma and the VE
congener with the highest biological potency(5), failed to delay
the onset of dementia(6) and to slow down the progression of
AD(7). Other clinical intervention studies employing high
dosage aT supplements, on the other hand, found a significant
reduction in AD progression(8,9).
Little is known regarding the long-term effects of dietary
VE on the expression of genes involved in the development
or prevention of AD and on the antioxidant status in the
healthy brain. The aim of the present study was therefore to
investigate (i) whether suboptimal supply of dietary VE may
cause unfavourable physiological changes with regard to the
parameters of oxidative stress and the expression of genes rel-
evant in the pathogenesis of AD in the healthy brain, and (ii)
whether supplementation of a high dose of aT on top of
an already sufficient dietary supply of VE may induce
AD-preventive effects.
Materials and methods
Experimental diets
The tocopherol-rich rapeseed variety S-NAP 944 (a kind gift
from Norddeutsche Pflanzenzucht Hans-Georg Lembke KG,
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Abbreviations: AD, Alzheimer’s disease; APP, amyloid b-(A4) precursor protein; Bax, Bcl-2-associated X protein; Bcl-2, B-cell leukaemia/lymphoma 2; BHT,
butylated hydroxytoluene; dVE, vitamin E deficient; fVE, vitamin E fortified; HO-1, haeme oxygenase 1; mVE, vitamin E marginal; sVE, vitamin E sufficient;
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Holtsee, Germany) was cold pressed under a nitrogen
atmosphere. The resulting oil was vacuum filtered and
contained 341mg aT, 386mg gT and 11mg d-tocopherol
per kg oil. A part of the native rapeseed oil was stripped of
tocopherols by column chromatography as described by
Lampi et al. (10). The fatty acid composition of the oil (oleic
acid, 49·1% of total fatty acids; linoleic acid, 19·7%; linolenic
acid, 10·8%; erucic acid, 7·2%; gadoleic acid, 4·9%; palmitic
acid, 4·5%) was not altered by the removal of antioxidants
(data not shown). The tocopherol-stripped oil was used as fol-
lows: (i) unmodified or (ii) blended at a ratio of 1:1 with the
native oil, (iii) the native oil was used unaltered or (iv) forti-
fied with 4 g natural RRR-a-tocopherol (a kind gift of Cognis,
Monheim am Rhein, Germany) per kg oil. Butylated hydroxy-
toluene (BHT 200mg/kg; Carl Roth GmbH, Karlsruhe,
Germany) was added to all oils as a preservative to protect
the tocopherols from oxidative decay.
These oils were used to prepare diets (ssniff Spezialdiaeten
GmbH, Soest, Germany) with VE concentrations that, accord-
ing to the Nutrient Requirements of Laboratory Rats (11), can
be classified as VE deficient (dVE), marginal (mVE), suffi-
cient (sVE) and fortified (fVE).
The composition of the four semi-synthetic experimental
diets was as follows (g/kg diet): casein, 240; maize starch,
modified, 480; glucose, 110; cellulose, 50; VE-free vitamin
premix (E15313-2), 10; mineral premix (E15000), 60;
rapeseed oil, 50. All VE in the experimental diets originated
from the rapeseed oil and were as follows (as analysed
by HPLC and given in mg/kg diet). dVE: aT, ,1; gT,
,1; mVE: aT, 6; gT, 11; sVE: aT, 12; gT, 24; fVE: aT,
140; gT, 24.
Experimental animals and study design
The animal experiment was conducted in accordance with
the German regulations on animal care and with the per-
mission of the responsible authority. Thirty-two male
Fisher 344 rats (Charles River Laboratories, Sulzfeld,
Germany) with a mean initial body weight of 51 (SD 5) g
were randomly divided into four groups of eight animals
each and fed the experimental diets for 6 months. The
rats were housed in Makrolon III cages in a conditioned
room (22 ^ 28C, 55% relative humidity, 12 h light–dark
cycle). The animals had free access to tap water and the
experimental diets throughout the experiment. Food con-
sumption and animal weight were recorded daily and
weekly, respectively. At the end of the experiment, the
rats were fasted for 12 h before CO2–anaesthesia and
decapitation. Blood samples were collected in tubes contain-
ing heparin as anticoagulant and plasma was obtained by
centrifugation (48C, 3000 g, 10min) and stored at 2808C
until analysed. The brain was excised and dissected; one
part of the cortex and the hippocampus were stored in RNA-
later (Qiagen, Hilden, Germany). The remaining brain was
snap frozen in liquid nitrogen and stored at 2808C.
Quantification of tocopherols
Tissues (100mg) were weighed into test tubes with screw caps
on ice. Ethanol (2ml) containing 1% (by weight) ascorbic
acid, 700ml H2O and 300ml saturated aqueous KOH were
added. The samples were saponified at 708C in a shaking
water-bath for 30min and then cooled on ice. Fifty microlitres
of BHT (1mg/ml) and 2ml of n-hexane were added, and
the samples were centrifuged (167 g, 48C, 5min) to aid
phase separation. One millilitre of the supernatant was trans-
ferred to a clean tube and dried under a stream of nitrogen
gas. The residue was dissolved in 250ml mobile phase (metha-
nol–water (98:2, v/v)) and injected into the HPLC system.
Plasma samples (100ml) were processed as described
previously, but without saponification. Tocopherols were
analysed using a Jasco (Gross-Umstadt, Germany) HPLC
system (pump PU2080Plus, autosampler AS2057Plus,
detector FP2020Plus). The separation of tocopherols was
performed on a Waters Spherisorb ODS-2 column
(100mm £ 4·6mm, 3mm). The fluorescence detector was set
to an excitation wavelength of 296 nm and emission wave-
length of 325 nm. The concentrations of aT and gT were
quantified by the use of authentic tocopherols (Calbiochem,
Schwalbach, Germany) as external standards (limit of
quantification,<50 pg). Analyses were performed in duplicate.
Porcine plasma with known concentrations of aT and gT was
analysed in parallel as quality control. Plasma VE concen-
trations were normalised for plasma cholesterol concentration,
which was determined spectrophotometrically using a com-
mercial kit (Fluitestw CHOL 4241, Biocon Diagnostik,
Voehl/Marienhagen, Germany), according to the manufac-
turer’s protocol.
Determination of rat cortex concentrations of F2-isoprostanes
Cortex samples were homogenised using Dounce homogen-
iser to yield 10% homogenates in 180mM-KCl, 10mM-
EDTA and 0·1mM-BHT (pH 7·4). To hydrolyse esterified
F2-isoprostanes, the cortex homogenates (100ml) were trea-
ted with 4M-KOH at 458C for 30min and neutralised
by the addition of 4M-HCl (pH adjusted to 2·0 with
0·1M-HCl). 9a,11a-PGF2a-d4 (0·5 ng; Cayman Chem. Co.,
Ann Arbor, MI, USA) was used as an internal standard.
Fatty acids, including isoprostanes, were extracted two
times by ethyl acetate. The samples were centrifuged for
phase separation and the upper phases were applied onto
NH2 cartridges. Solid phase extraction and derivatisation
steps were performed as described previously(12). F2-isopros-
tanes were separated and measured by GC/negative-ion
chemical ionisation MS (DSQ/Trace GC Ultra; Thermo
Fisher Scientific, Dreieich, Germany) with ammonia as
reagent gas using selected ion monitoring of the carboxylate
anion [M-181] at m/z 569 and 573 for F2-isoprostanes and
the deuterated internal standard. The F2-isoprostane peak
co-eluted with authentic 8-iso-PGF2a, but it is known that
other F2-isoprostane isomers occur at the same retention
time(13). All analyses were performed in triplicate for each
tissue sample. The protein content was determined using
the method of Bradford(14).
Antioxidant enzyme activities and glutathione concentration in
the cortex
Cortex tissue (100mg) was diluted 1:10 (by weight) in ice-
cold PBS and homogenised. The homogenate was centrifuged
(3000 g, 48C, 10min), the supernatant collected and used
Vitamin E, redox status and gene regulation 399
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for the measurements after appropriate dilution in PBS.
Superoxide dismutase enzyme activity was measured accord-
ing to the method of Marklund & Marklund(15). Se-dependent
glutathione peroxidase activity was measured according to the
method of Lawrence & Burk(16) using bovine GPx (Sigma
Aldrich, Darmstadt, Germany) to generate the external stan-
dard curve. GSH concentrations were measured in homogen-
ates according to Tietze(17) with modifications(18). All
measurements were carried out on a DU 800 spectropho-
tometer (Beckman Coulter, Krefeld, Germany). Results for
antioxidant enzyme activities and GSH concentrations were
adjusted for protein content as assessed using a commercial
kit (BCA Protein Assay; Pierce, Rockford, IL, USA).
RNA isolation and real-time qRT-PCR
Total RNA was extracted according to the RNeasyw Lipid
Tissue Protocol (Qiagen). DNA digestion was performed
with the RNase-Free DNase Set (Qiagen). The concentration
of isolated RNA was spectrophotometrically determined
(Beckmann Instruments, Munich, Germany) by measuring
the absorbance at 260 nm; the purity was determined by the
ratio of 260 and 280 nm and a ratio of 1·6–1·9 was considered
as acceptable. RNA aliquots were stored at 2808C until PCR
analysis. Primer sequences for real-time RT-PCR experiments
were designed with Primer3 software (version 0.4.0; http://
frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Primer
pairs (Table 1) were obtained from MWG Biotech AG
(Ebersberg, Germany). The Bcl-2 primer was obtained from
Qiagen. One-step quantitative RT PCR was carried out with
the QuantiTecte SYBRw Green RT-PCR kit (Qiagen).
Real-time PCR amplification was performed in a Rotor-
Gene 3000 thermocycler (Corbett Research, Sydney,
Australia). Relative mRNA concentrations of genes were
quantified by the use of a standard curve. Target gene
mRNA concentration was normalised to the mRNA concen-
tration of the housekeeping gene b-actin.
Western blot experiments in the cortex homogenates
Cortex tissue (100mg) was homogenised in RIPA buffer
(NaCl, 150mM; sodium deoxycholate, 0·5%; SDS, 0·1%;
NP-40, 1%; EDTA, 20mM; 2-amino-2-hydroxymethyl-pro-
pane-1,3-diol (Tris)–HCl, 50mM (pH 7·4); dithiothreitol,
1mM; protease inhibitor cocktail). Lysates were purified by
centrifugation (14 000 g, 48C, 30min). Total protein concen-
trations in each lysate were quantified using a BCA Protein
Assay kit (Pierce). Total proteins of the lysate (40mg per
lane) were separated by SDS gel electrophoresis followed by
transferring the proteins to a PVDF membrane, which was
then blocked for 1·5 h in blocking buffer (5% non-fat milk
in Tris-buffered saline). Primary antibodies were diluted in
5% non-fat milk (Bax, Bcl-2, 1:200; b-actin, 1:1000) and
the blots were incubated overnight at 48C. The blots were
washed and incubated with secondary antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA; anti-mouse horseradish
peroxidase) in blocking buffer (Bax, Bcl-2, 1:5000; b-actin,
1:1000) with gentle agitation for 1 h at room temperature.
The blots were washed and exposed to Immun-Star Western
Chemiluminescent kit (Bio-Rad Laboratories, Hercules, CA,
USA) and scanned with a ChemiDoc (Bio-Rad). Digital
images were captured and quantified using the Quantity-One
system (Bio-Rad). Relative concentration of the proteins
were quantified as the ratio between the amount of target
protein and the amount of the housekeeping protein b-actin.
Statistical analysis
Statistical calculations were conducted with SPSS Version
13.0 (SPSS, Munich, Germany). For the comparison of
group means, one-way ANOVA was performed with the
Scheffe´ test (normal distribution, homogeneity of variances)
or the Games–Howell test (normal distribution, heterogeneity
of variances) as post hoc tests. When data were not normally
distributed, the Mann–Whitney U test was performed. Signifi-
cance was accepted at P,0·05.
Results
Feed intake and body weight gain
Total feed intake (data not shown) and final body weights
(means dVE, 362·8 (SD 11·5) g; mVE, 366·6 (SD 18·3) g;
sVE, 372·1 (SD 21·2) g; fVE, 349·9 (SD 21·0) g) did not
differ between the dietary groups.
Table 1. Nucleotide sequences of primers used for the real-time qRT-PCR experiments
Gene Primer sequence forward (50 –30) Primer sequence reverse (50 –30)
b-Actin GGG GTG TTG AAG GTC TCA AA TGT CAC CAA CTG GGA CGA TA
APP CAG CGT GTC ATC CCA AAG T GCG TGC TCG TTC TCA TCT C
Apba1 AGC AGT AAG CCG GAT CAA GA GAT CCT CTG GGT GGA GAT GA
ADAM-10 GGG CAA TGT GCA GGT TCT AT TGA ACT GCT TGT TCC ACT GC
BACE-1 AAT CAG TCC TTC CGC ATC AC GGC TCG ATC AAA GAC CAC AT
ECE CTA TGT CAG TGC CGA CTC CA CCC AGC TGG ACC ATG TAG TT
IDE TCA AAG GGC TGG GTA AAC AC CCT TGC ACT CTT GGA AAA CC
NEP ACC TAG CAG GTG GAC AGC AT ACA CCT GGG CAA AGT TCA AG
Bax AGC TGC AGA GGA TGA TTG CT GAT CAG CTC GGG CAC TTT AG
AChE CAG CAA TAC GTG AGC CTG AA TTC CAG TGC ACC ATG TAG GA
aTTP GCT TTT CAA ATT ACC CCA TC GAT CCC ACG AAC TTT CAA TG
HO-1 GGG TGA CAG AAG AGG CTA AG GCT GAT CTG GGA TTT TCC TC
APP, amyloid b-(A4) precursor protein; Apba1, APP-binding family member 1; ADAM-10, a disintegrin and
metalloprotease domain 10; BACE-1, b-site amyloid b-(A4) precursor protein-cleaving enzyme 1; ECE,
endothelin-converting enzyme; IDE, insulin-degrading enzyme; NEP, neprilysin; AChE, acetylcholinester-
ase; aTTP, a-tocopherol transfer protein; HO-1, haeme oxygenase 1.
S. Gaedicke et al.400
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Plasma and tissue concentrations of a- and g-tocopherols
Plasma concentrations of total cholesterol were significantly
lower in the dVE group than in the mVE (P,0·05) and fVE
(P,0·001) groups (means dVE, 2·23 (SD 0·22) mmol/l;
mVE, 2·6 (SD 0·24) mmol/l; sVE, 2·51 (SD 0·17) mmol/l;
fVE, 2·80 (SD 0·24) mmol/l; one-way ANOVA with Scheffe´
post hoc test) and were used to normalise plasma tocopherol
concentrations. Consumption of the experimental diets with
graded concentrations of VE for 6 months significantly and
dose dependently affected aT concentrations in the plasma,
lung, muscle, cortex and hippocampus of male Fisher
344 rats (Table 2).
F2-isoprostanes and antioxidant enzymes in the cortex
The concentrations of F2-isoprostanes in the cortex homogen-
ates were not significantly different between the dietary
groups (Fig. 1).
Superoxide dismutase and glutathione peroxidase activities
as well as glutathione concentrations in the cortices of the
rats were similar in all groups (Table 3).
Gene expression in cortex and hippocampus
In the cortex and hippocampus, the differences in dietary
supply with VE did not result in significant changes in relative
mRNA concentrations of amyloid b-(A4) precursor protein
(APP), APP-binding family member 1, a disintegrin and
metalloprotease domain 10, b-site APP-cleaving enzyme 1,
endothelin-converting enzyme, insulin-degrading enzyme,
neprilysin, Bax (Bcl-2-associated X protein), Bcl-2 (B-cell
leukaemia/lymphoma 2), acetylcholinesterase, aTTP (a-toco-
pherol transfer protein) and HO-1 (haeme oxygenase 1)
(Table 4).
Protein concentrations of apoptosis markers in the cortex
homogenates
Protein concentrations of Bcl-2 and Bax in the cortex did
not differ between the groups (Fig. 2). Protein concentrations
of activated caspases 3 and 8 were undetectable (data
not shown).
Discussion
Epidemiological as well as clinical intervention studies indi-
cate that a high intake of VE may be important for the preven-
tion of age-related neurodegenerative disorders such as
AD(19). Of the different tocopherols present in foods, RRR-
a-tocopherol is thought to be the most important to human
health and has the highest VE activity in human and animal
systems(5). Plant oils are the major dietary source of tocopher-
ols and rapeseed oil, due to its high concentrations of toco-
pherols and n-3 fatty acids(20), is considered of high value
for human nutrition. Therefore, in the present study, we inves-
tigated the effects of graded dietary concentrations of VE from
rapeseed oil on the antioxidant status and the regulation of
genes relevant in the pathogenesis of AD in the brains
of Fisher 344 rats during growth and maturation. During
the 6-month feeding period of the present experiment, no
differences in feed intake and life weight gain were observed
between the dietary groups, which is in accordance with our
previous findings(21).
Vitamin E in plasma and tissues
In correspondence with the intake of aT, we observed dose-
dependent changes in the concentrations of aT in the brain
(cortex and hippocampus), plasma and other tissues in our
rats (Fig. 1). In accordance with the data from the previously
Table 2. Tocopherol concentrations in the plasma, lung, muscle, cortex and hippocampus of rats fed diets deficient (dVE), marginal
(mVE) or sufficient (sVE) in vitamin E or fortified (fVE) with a-tocopherol (aT) for 6 months
(Mean values with their standard errors, n 8 except where indicated differently)
Diet
dVE mVE sVE fVE
Tissue Mean SEM Mean SEM Mean SEM Mean SEM P
Plasma n 8 n 8 n 8 n 8
aT (nmol/ml) 0·34a 0·01 10·8b 0·49 17·7c 0·43 38·1d 1·26 ,0·001
gT (nmol/ml) 0·01a 0·001 0·57b 0·01 0·55b 0·02 0·07c 0·01 ,0·001
aT (nmol/mol cholesterol) 0·15a 0·002 4·15a 0·09 7·05c 0·15 13·6d 0·18 ,0·001
gT (nmol/mol cholesterol) ,0·01a 0·22b 0·01 0·22b 0·01 0·02C 0·002 ,0·001
Lung (nmol/g)
aT 0·40a 0·04 12·1b 0·39 21·2c 1·24 43·1d 1·21 ,0·001
gT 0·04a 0·02 0·54b 0·02 0·65c 0·03 0·09a 0·02 ,0·05
Muscle (nmol/g)
aT 0·39a 0·04 7·37b 0·28 11·4c 0·64 20·0d 0·92 ,0·001
gT 0·03a 0·004 0·21b 0·01 0·36c 0·03 0·06d 0·005 ,0·05
Cortex (nmol/g) n 8 n 8 n 6 n 8
aT 3·78a 0·44 16·7b 0·97 21·2b 1·27 30·0c 1·59 ,0·001
gT 0·01a 0·001 0·13b 0·01 0·16b 0·01 0·05c 0·005 ,0·001
Hippocampus (nmol/g) n 7 n 6 n 5 n 6
aT 2·00a 0·39 7·86a,b 1·60 9·64b,c 1·30 15·6c 1·52 ,0·05
gT ND ND ND ND
gT, g tocopherol.
a,b,c Mean values within a row with unlike superscript letters are statistically different at P.
Vitamin E, redox status and gene regulation 401
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published rat experiments(22,23), the changes in aT concen-
trations in the brain, however, were less pronounced than
the changes observed in all other tissues. Similarly, in
Parkinson’s disease patients who, over a period of 5 months,
consumed high amounts of aT (from 400 IU/d (364 mg all-
rac-a-tocopherol/d) during the first month to 4000 IU/d
(3636 mg all-rac-a-tocopherol/d) during the last month of sup-
plementation), Pappert et al. (24) observed large increases in
aT concentrations in plasma (from 19 to 111mmol/l), while
its concentrations in ventricular cerebrospinal fluid remained
unchanged (in a range of 0·114–0·164mmol/l).
In our rats, a deficient supply of aT (,1mg/kg diet) resulted
in an almost complete depletion of aT in the plasma (0·15 (SD
0·002) mmol/mol cholesterol), while again changes in the brain
were less pronounced (Table 2). In the cortex and hippocampus,
3·7 (SD 0·4) and 2·0 (SD 0·4) nmol aT/g tissue, respectively,
were retained even after 6 months of deficient VE intake.
These data are in agreement with the results of Clement
et al. (25), who fed rats from VE-deficient mothers a VE-
deficient diet for 8 weeks, and observed a marked reduction
in the concentrations of aT in the serum, liver and muscle,
while significant concentrations of aT were preserved in all
analysed nervous tissues. Vatassery et al. (22) observed that
even though other tissues could be almost completely depleted
of aT by feeding of a VE-deficient diet for 4 months, in the
brain low levels of aT were retained. Together, these and the
present results suggest that the brain is especially efficient at
maintaining aT within a certain physiological range, prevent-
ing both excessive aT accumulation and its depletion.
In the present study, the dVE, mVE and sVE diets provided
increasing concentrations of aT and gT. The fVE diet, on the
other hand, was prepared by the addition of aT to the natural
rapeseed oil and thus provided the same amount of gT as the
sVE diet but about 10£ more aT. With decreasing gT concen-
trations in the dVE, mVE and sVE diets, we observed dose-
dependent decreases in the concentrations of gT in the lung,
muscle and cortex tissue, but not in the plasma. Interestingly,
the fVE-fed rats consuming additional aT also had signifi-
cantly reduced plasma and tissue gT concentrations compared
with the sVE-fed rats despite a similar gT intake (Table 2).
In the human system, the phenomenon of reduced gT concen-
trations caused by a high intake of aT was first described by
Handelman and co-workers. In eighty-six subjects (.50 years
of age, mean age 71·8 (SD 6·4)), they observed an inverse
relationship between aT and gT concentrations in the
plasma. Supplementation of eight volunteers (30–60 years
of age) with 1200 IU (1091 mg) all-rac-aT per day for
8 weeks resulted in a significant increase in plasma aT and
a significant decrease in gT(26). These findings were later con-
firmed in human subjects by other researchers(27,28) and are
thought to be the result of an induction of cytochrome P450
enzymes, which are involved in VE metabolism and preferen-
tially degrade the desmethyl vitamers(29).
F2-isoprostanes
With increasing age, lipid peroxidation of membrane fatty
acids in the brain appears to augment(30) and oxidative
stress in the brain is thought to be an important factor in
the pathology of AD(19). Accordingly, the concentrations
of F2-isoprostanes, which are non-enzymatic free-radical-
induced peroxidation products of arachidonic acid(31), have
been found to be significantly higher in the cerebrospinal
fluid or brains of AD patients than those of matched healthy
controls(32). We investigated the effects of increasing doses
of dietary VE on F2-isoprostane concentrations in the
cortex of male Fisher 344 rats and found a non-significant
trend towards higher F2-isoprostane concentrations in the
group fed the dVE diet, but overall no significant
differences were observed between the dietary groups
(Fig. 1). Similar to our findings, Cuddihy et al. did not
observe significant differences between the F2-isoprostane
Fig. 1. F2-isoprostane concentrations (ng/mg protein) in the cortex of Fisher
344 rats fed diets deficient (dVE), marginal (mVE) or sufficient (sVE) in vita-
min E (VE) or fortified (fVE) with a-tocopherol for 6 months. Values are
represented as means with their standard errors (n 8). No statistical differ-
ences were observed.
Table 3. Antioxidant enzyme activities and glutathione concentrations in the cortex of rats fed diets
deficient (dVE), marginal (mVE) or sufficient (sVE) in vitamin E or fortified (fVE) with a-tocopherol for
6 months*
(Mean values with their standard errors, n 8)
Diet
dVE mVE sVE fVE
Enzyme Mean SEM Mean SEM Mean SEM Mean SEM
SOD (U/mg protein) 13·8 0·77 13·0 0·79 13·5 0·51 14·2 0·55
SeGPx (mU/mg protein) 88·0 4·67 95·6 5·20 90·4 4·35 98·0 6·61
GSH (nmol/mg protein) 24·9 1·40 25·1 0·76 23·9 0·76 26·0 0·49
SOD, superoxide dismutase; SeGPx, Se-dependent glutathione peroxidase.
*No statistical differences were observed.
S. Gaedicke et al.402
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concentrations in the cortices of mice fed dVE or sVE diets
for 40 weeks. Surprisingly, cortex concentrations of F4-neu-
roprostanes, which are oxidation products of DHA (22:6), an
abundant fatty acid in the brain, were positively correlated
with aT concentrations(33).
The present results indicate that the low concentrations of
aT retained in the brain may have been sufficient to protect
the cortex from lipid peroxidation.
Another aim of the present study was to investigate whether
or not the intake of different amounts of VE may influence the
activity of antioxidative enzymes and modulate cellular gluta-
thione levels. Activities of total superoxide dismutase and Se-
dependent glutathione peroxidase as well as concentrations of
total GSH in the cortices of our rats did not differ between the
experimental groups. It appears likely that the lack of oxi-
dative stress in our animals may be responsible for the absence
Table 4. Relative mRNA expression (corrected for the housekeeping gene b-actin) of Alzheimer’s disease-relevant genes in the cortex and hippo-
campus of rats fed diets deficient (dVE), marginal (mVE) or sufficient (sVE) in vitamin E or fortified (fVE) with a-tocopherol for 6 months*
(Mean values with their standard errors, n 8)
Cortex Hippocampus
dVE mVE sVE fVE dVE mVE sVE fVE
Gene Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
APP 1·21 0·06 1·13 0·08 1·13 0·10 1·21 0·04 0·89 0·08 0·88 0·04 1·01 0·08 0·95 0·07
Apba1 1·06 0·11 1·13 0·11 1·35 0·14 1·16 0·09 0·94 0·06 0·92 0·06 0·95 0·08 0·95 0·06
ADAM-10 0·94 0·08 0·91 0·08 1·06 0·06 0·97 0·08 0·90 0·06 0·83 0·03 1·00 0·04 0·83 0·05
BACE-1 0·96 0·07 0·88 0·09 1·06 0·08 0·98 0·08 0·79 0·06 0·79 0·03 0·76 0·04 0·73 0·02
Bax 0·94 0·04 0·89 0·07 1·08 0·07 0·96 0·03 1·02 0·08 0·84 0·03 0·90 0·02 0·90 0·04
Bcl-2 1·09 0·05 1·04 0·05 1·16 0·07 1·14 0·05 1·15 0·08 1·01 0·04 1·15 0·05 1·08 0·05
ECE 1·03 0·06 0·87 0·05 1·10 0·09 0·96 0·04 0·95 0·06 0·90 0·04 0·95 0·04 0·89 0·05
IDE 0·92 0·04 0·86 0·07 1·07 0·06 0·97 0·08 0·93 0·12 0·88 0·07 0·99 0·08 0·86 0·09
Neprilysin 1·58 0·29 1·18 0·30 1·25 0·17 1·12 0·06 0·88 0·07 0·98 0·06 0·94 0·05 0·89 0·05
aTTP 1·06 0·06 1·08 0·09 1·17 0·11 1·10 0·06 0·99 0·07 0·91 0·04 1·01 0·09 1·02 0·05
HO-1 1·35 0·09 1·39 0·10 1·45 0·13 1·31 0·11 0·85 0·10 0·68 0·06 0·81 0·05 0·63 0·04
AChE 1·35 0·23 1·04 0·09 1·11 0·06 1·27 0·10 0·96 0·06 1·02 0·10 1·05 0·06 0·94 0·07
APP, amyloid b-(A4) precursor protein; Apba1, APP-binding family member 1; ADAM-10, a disintegrin and metalloprotease domain 10; BACE-1, b-site amyloid b-(A4) precur-
sor protein-cleaving enzyme 1; ECE, endothelin-converting enzyme; IDE, insulin-degrading enzyme; aTTP, a-tocopherol transfer protein; HO-1, haeme oxygenase 1; AChE,
acetylcholinesterase.
*No statistical differences were observed.
Fig. 2. (A) B-cell leukaemia/lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax) and b-actin protein concentrations in the cortex homogenates and (B) relative
concentration of Bcl-2 ( ) and Bax ( ) of rats fed diets deficient (dVE), marginal (mVE) or sufficient (sVE) in vitamin E (VE) or fortified (fVE) with a-tocopherol
for 6 months. b-Actin served as endogenous (loading) control. Values are represented as means with their standard errors (n 6).
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of the differences in the activities and concentrations, respect-
ively, of antioxidant enzymes. Supplementation with aT (fVE
group) did not result in enhanced enzyme activities or concen-
trations, either. However, there is no consistent opinion
regarding this in the literature: while some groups report no
changes in antioxidative enzyme activities or concen-
trations(34), others report increases in the activities or concen-
trations of antioxidant enzymes caused by VE depletion(35), as
well as supplementation(36).
Gene expression
The accumulation and aggregation of misfolded proteins
(particularly amyloid-b), the loss of neurons due to pro-
grammed cell death (e.g. apoptosis) and impaired neuronal
signal transduction in specific parts of the brain are major
pathological features of AD(1). Therefore, we measured
mRNA concentrations of genes involved in the formation
(APP-binding family member 1, a disintegrin and metallopro-
tease domain 10, b-site APP-cleaving enzyme 1) or
degradation (neprilysin, insulin-degrading enzyme, endothe-
lin-converting enzyme) of amyloid-b, programmed cell
death (Bcl-2, Bax) and neurotransmitter degradation (acetyl-
cholinesterase) in the brains of our rats.
In the cortex and hippocampus of our rats, dietary VE did not
affect mRNA concentrations of the measured genes (Table 4).
Some of the analysed genes (e.g. acetylcholinesterase, b-site
APP-cleaving enzyme 1)(37,38) are thought to be regulated by
oxidative stress, others experience age-related loss of activity
and/or protein concentration (neprilysin, insulin-degrading
enzyme)(39,40). As an additional biomarker for oxidative stress,
we determined haeme oxygenase type 1 (HO-1) mRNA concen-
trations in the brains of our rats. HO-1 is up-regulated in the situ-
ations of oxidative and nitrosative stress, presenting a
cytoprotective effect against various forms of stress by releasing
the vasoactivemolecule carbonmonoxide and the potent antiox-
idant bilirubin(41). A significantly higher expression of HO-1
was observed in the neurons and astrocytes of AD hippocampus
and cerebral cortex samples relative to age-matched controls(42).
Consistent with our F2-isoprostane data, mRNA concentrations
of HO-1 were not affected by VE depletion or supplementation,
indicating the absence of oxidative stress in the rat brains in the
present study.
aTTP mRNA has been found in the human and rat brains,
although at lower concentrations than in the liver(43,44). The
exact function of aTTP in the brain is not known, but it
was suggested to function in maintaining aT concentrations
in the brain(45). In the present study, aTTP mRNA concen-
trations were not changed by VE depletion or by aT sup-
plementation. Other groups, however, observed that VE
deficiency led to transcriptional alterations in the cortex(46)
and hippocampus(47) of rats, as well as in aTTP2/2
mice(48). Rota et al. (47) have shown that certain genes related
to the pathophysiology of neurodegenerative diseases were
regulated in rat hippocampi by dietary VE. One main differ-
ence between these two studies is that we fed our rats for 6
months, while Rota et al. fed theirs for 9 months. In both
studies, however, animals fed a VE-deficient diet had signifi-
cantly reduced VE concentrations in the plasma and hippo-
campus, although the VE depletion of the brains remained
incomplete, suggesting that the brain has a strong capability
to retain VE. Additionally, the diets in our trial contained
the synthetic antioxidant BHT to protect the diets from lipid
peroxidation during storage and BHT might have exerted
additional antioxidant effects in our rats by direct scavenging
of reactive species and/or regenerating aT from its radical
form(49). However, with 10mg/kg, the concentration of BHT
in our diets was low compared with 2000–4000mg/kg diet
employed in the rat studies where antioxidant effects of
BHT were observed(50,51). BHT is extensively metabolised
in the liver, and both BHT and its metabolites are excreted
with the bile, faeces and urine, which in turn results in a
low rate of tissue accumulation of BHT(52–54). Hence, poten-
tial antioxidant effects of BHT are likely to be more potent in
the liver than in the extra-hepatic tissues. However, hepatic
HO-1 mRNA concentrations were significantly higher in the
dVE than in the sVE animals in conjunction with reduced
micro-RNA expression(55). Therefore, the absence of oxidative
stress, as assessed by the concentrations of F2-isoprostanes and
relative mRNA levels of HO-1, in the brains of our VE-
depleted as well as aT-supplemented rats compared with con-
trol (sVE) is unlikely to be a result of the BHT in the diet.
Apoptosis seems to be an important process in AD, as
suggested by increased levels of apoptosis markers in the
brains of AD patients(56). Bcl-2 and Bax, anti- and pro-apop-
totic members, respectively, of the Bcl-2 family of signalling
molecules, play a central role in apoptotic cell death. Both
proteins function independently to regulate cell death, but
can also form heterodimers. Therefore, the ratio of Bcl-2 to
Bax is indicative of a pro- or anti-apoptotic cell status(57).
In the present study, neither Bcl-2 nor Bax mRNA (Table 4)
and protein (Fig. 2) concentrations were different depending
on the diet.
Conclusions
The present data suggest that stepwise reduction in dietary aT
and gT for 6 months does not impair antioxidant status, induce
apoptosis or alter the expression of selected genes in the brains
of rats. Similarly, aT supplementation of already sVE animals
does not improve antioxidant status, affect apoptosis or alter
the expression of AD-relevant genes. In conclusion, VE
does not appear to change the parameters involved in the
aetiology and progression of AD in healthy animals. Further-
more, investigations into the impact of VE on these
parameters in an AD disease model are warranted.
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